colorectal {SLCARE}

Follow-up of metastatic colorectal cancer patients: times of new lesions appearance and death

Description

Randomly chosen 150 patients from the follow-up of the FFCD 2000-05 multicenter phase III clinical trial originally including 410 patients with metastatic colorectal cancer randomized into two therapeutic strategies: combination and sequential. The dataset contains times of observed appearances of new lesions censored by a terminal event (death or right-censoring) with baseline characteristics (treatment arm, age, WHO performance status and previous resection).

Usage

data(colorectal)

Format

This data frame contains the following columns:

id

identification of each subject. Repeated for each recurrence

time0

start of interval (0 or previous recurrence time)

time1

recurrence or censoring time

new.lesions

Appearance of new lesions status. 0: censsored or no event, 1: new lesions

treatment

To which treatment arm a patient was allocated? 1: sequential (S); 2: combination (C)

age

Age at baseline: 1: <50 years, 2: 50-69 years, 3: >69 years

who.PS

WHO performance status at baseline: 1: status 0, 2: status 1, 3: status 2

prev.resection

Previous resection of the primate tumor? 0: No, 1: Yes

state

death indicator. 0: alive, 1: dead

gap.time

interocurrence time or censoring time

Note

This dataset was originally publicly available in frailtypack package (Rondeau et al. 2012). Unfortunately the 'frailtypack" is not available on CRAN at the time we create SLCARE. We tentatively integrate this dataset to our package. The archive version of fraitypack on CRAN can be find at https://CRAN.R-project.org/package=frailtypack

References

M. Ducreux, D. Malka, J. Mendiboure, P.-L. Etienne, P. Texereau, D. Auby, P. Rougier, M. Gasmi, M. Castaing, M. Abbas, P. Michel, D. Gargot, A. Azzedine, C. Lombard- Bohas, P. Geoffroy, B. Denis, J.-P., Pignon, L.,Bedenne, and O. Bouche (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. The Lancet Oncology 12, 1032-44.